Cargando…

Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)

PURPOSE: Visual acuity (VA) of the amblyopic eye is usually considered for monitoring improvement with therapy. However, participation of the amblyopic eye under binocular viewing conditions is also important. This study investigated the use of a clinically available tool VTS4 (Vision Therapy System...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehgal, Shivalika, Satgunam, PremNandhini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683859/
https://www.ncbi.nlm.nih.gov/pubmed/33244444
http://dx.doi.org/10.1167/tvst.9.12.24
_version_ 1783612970807328768
author Sehgal, Shivalika
Satgunam, PremNandhini
author_facet Sehgal, Shivalika
Satgunam, PremNandhini
author_sort Sehgal, Shivalika
collection PubMed
description PURPOSE: Visual acuity (VA) of the amblyopic eye is usually considered for monitoring improvement with therapy. However, participation of the amblyopic eye under binocular viewing conditions is also important. This study investigated the use of a clinically available tool VTS4 (Vision Therapy System 4) to quantify the participation or suppression of the amblyopic eye under binocular viewing conditions. METHODS: A cross-sectional study on patients with anisometropic amblyopia was undertaken. Monocular VA was thresholded. Stereo acuity was measured with Randot stereo test. Simultaneous macular perception (SMP) targets in VTS4 were dichoptically presented. SMP target size was reduced till the amblyopic eye's target disappeared (suppression scotoma size). An average of three measurements was taken for the suppression scotoma size. RESULTS: Twenty-eight patients participated (aged 6 to 21 years). The mean interocular VA difference was 0.50 ± 0.27 logMAR. The mean scotoma size was 8.2° ± 5.4°. Mean stereo acuity was 2.06 ± 0.34 log arc seconds from 21 patients on whom stereopsis could be measured. Suppression scotoma size showed a significant (P < 0.001) positive correlation with both interocular VA difference (r = 0.59) and stereoacuity (r = 0.72). CONCLUSIONS: Participation of the amblyopic eye under binocular viewing condition can be assessed by measuring the suppression scotoma size in VTS4, even when stereoacuity is poor or not measurable. Smaller the suppression scotoma, better is the amblyopic eye's participation. TRANSLATIONAL RELEVANCE: VTS4 can be used in monitoring amblyopia therapy by quantifying suppression of the amblyopic eye.
format Online
Article
Text
id pubmed-7683859
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-76838592020-11-25 Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4) Sehgal, Shivalika Satgunam, PremNandhini Transl Vis Sci Technol Article PURPOSE: Visual acuity (VA) of the amblyopic eye is usually considered for monitoring improvement with therapy. However, participation of the amblyopic eye under binocular viewing conditions is also important. This study investigated the use of a clinically available tool VTS4 (Vision Therapy System 4) to quantify the participation or suppression of the amblyopic eye under binocular viewing conditions. METHODS: A cross-sectional study on patients with anisometropic amblyopia was undertaken. Monocular VA was thresholded. Stereo acuity was measured with Randot stereo test. Simultaneous macular perception (SMP) targets in VTS4 were dichoptically presented. SMP target size was reduced till the amblyopic eye's target disappeared (suppression scotoma size). An average of three measurements was taken for the suppression scotoma size. RESULTS: Twenty-eight patients participated (aged 6 to 21 years). The mean interocular VA difference was 0.50 ± 0.27 logMAR. The mean scotoma size was 8.2° ± 5.4°. Mean stereo acuity was 2.06 ± 0.34 log arc seconds from 21 patients on whom stereopsis could be measured. Suppression scotoma size showed a significant (P < 0.001) positive correlation with both interocular VA difference (r = 0.59) and stereoacuity (r = 0.72). CONCLUSIONS: Participation of the amblyopic eye under binocular viewing condition can be assessed by measuring the suppression scotoma size in VTS4, even when stereoacuity is poor or not measurable. Smaller the suppression scotoma, better is the amblyopic eye's participation. TRANSLATIONAL RELEVANCE: VTS4 can be used in monitoring amblyopia therapy by quantifying suppression of the amblyopic eye. The Association for Research in Vision and Ophthalmology 2020-11-19 /pmc/articles/PMC7683859/ /pubmed/33244444 http://dx.doi.org/10.1167/tvst.9.12.24 Text en Copyright 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Article
Sehgal, Shivalika
Satgunam, PremNandhini
Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)
title Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)
title_full Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)
title_fullStr Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)
title_full_unstemmed Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)
title_short Quantifying Suppression in Anisometropic Amblyopia With VTS4 (Vision Therapy System 4)
title_sort quantifying suppression in anisometropic amblyopia with vts4 (vision therapy system 4)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683859/
https://www.ncbi.nlm.nih.gov/pubmed/33244444
http://dx.doi.org/10.1167/tvst.9.12.24
work_keys_str_mv AT sehgalshivalika quantifyingsuppressioninanisometropicamblyopiawithvts4visiontherapysystem4
AT satgunampremnandhini quantifyingsuppressioninanisometropicamblyopiawithvts4visiontherapysystem4